CMS physics technical design report : Addendum on high density QCD with heavy ions

Peer reviewe

Multiplayer game backends: A Comparison of commodity cloud-based approaches

The development of resource-intensive complex distributed systems such as the backend side of Massively Multiplayer Online Games (MMOGs) has shifted towards cloud-based approaches in recent years. Despite this shift, researchers and developers have mostly utilized proprietary clouds to provide services for such applications — thus leaving the area of commodity clouds largely unexplored. The use of proprietary clouds is almost always applied at the Infrastructure-as-a-Service layer, thereby enforcing restrictions on the development of MMOGs. In a previous work we focused on the characteristics of MMOGs, outlining certain factors that prohibit their deployment on commodity clouds. In this paper, we evaluate the suitability of common public cloud platforms in developing and deploying the backend side of MMOGs. In our approach, we implement a simple MMOG over three popular public cloud platforms. Then, we evaluate their performance by measuring the latency of the game over each platform as well as the maximum size of game worlds supported by each approach. Our measurements show that approaches based on the Infrastructure-as-a-Service layer perform better than those based on the Platform-as-a-Service layer — which was expected. However, our results indicate that MMOGs based on the Platform-as-aService layer can also perform relatively well and within the bounds of real-time latency. Coupled with accelerated development and lower maintenance costs, Platform-as-a-Service technology paves the way for further development of MMOG specific Backend-as-a-Service platforms

Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–15

International audienc

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk